For research use only. Not for use in humans.

Anti-PDGFRB / CD140b (IMC-2C5)

Synonyms: IMC-2C5

Anti-PDGFRB / CD140b (IMC-2C5) is a fully human antagonistic antibody targeting PDGFRβ It enhances antitumor activity and antiangiogenic agents in the treatment of a broad range of human cancers. MW :145.06 KD.

Anti-PDGFRB / CD140b (IMC-2C5)

Quality Control

Batch: A304301 Purity: 99% Protein concentration: 8.7mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation PDGFR PDGFRα PDGFRβ Others
Dovitinib (TKI-258) 52 FLT3,c-Kit,VEGFR3/FLT4
Linifanib (ABT-869) 33 VEGFR1/FLT1,CSF-1R,VEGFR2/KDR
Crenolanib (CP-868596) 99
Masitinib 42 Kit,Lyn B,Abl1
Amuvatinib (MP-470) 21 c-Kit (D816H),FLT3 (D835Y)
Motesanib Diphosphate (AMG-706) 12 VEGFR1,VEGFR2,VEGFR2/Flk1
Orantinib (SU6668) 21
CP-673451 36
Ki8751 21 VEGFR2,c-Kit
Telatinib 5 c-Kit,VEGFR3,VEGFR2
PP121 5 Hck,VEGFR,mTOR
MK-2461 4 c-Met (M1250T),c-Met (Y1235D),c-Met (Y1230H)
Tyrphostin AG 1296 14 c-Kit (Swiss 3T3),FGFR (Swiss 3T3)
Tyrphostin 9 1 EGFR
Dovitinib (TKI258) Lactate monohydrate 31 FLT3,c-Kit,FGFR1
AZD2932 3 Flt3,VEGFR-2,c-Kit
Sennoside B 0
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Anti-PDGFRB / CD140b (IMC-2C5) is a fully human antagonistic antibody targeting PDGFRβ It enhances antitumor activity and antiangiogenic agents in the treatment of a broad range of human cancers. MW :145.06 KD.
References

Product Details

Isotype Human IgG1
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.